MYH9 and ovarian carcinoma: MiR-6089 also targets MYH9 and its overexpression suppresses ovarian cancer cell proliferation, migration, invasion, and metastasis in vivo and in vitro, and miR-6089 negatively correlates with MYH9 expression in clinical samples.